Table 2.
Characteristics of a comparison between matched patients with new-onset AKI and their controls without AKI
| Variables | New-onset AKI (n = 788) |
Non-AKI (n = 788) |
p value | Standardized difference (%) |
|---|---|---|---|---|
| Male | 500 (63.5%) | 524 (66.5%) | 0.21 | 4.26 |
| Age (years) | 66 (53–78) | 68 (53–79) | 0.14 | 4.47 |
| BMI (kg/m2) | 22.5 (19.6–24.2) | 22.5 (20.0–24.5) | 0.42 | 1.81 |
| COPD/asthma | 73 (9.3%) | 66 (8.4%) | 0.53 | − 0.93 |
| Cardiovascular disease | 143 (18.1%) | 154 (19.5%) | 0.48 | 3.75 |
| Hypertension | 291 (36.9%) | 305 (51.2%) | 0.47 | 4.11 |
| Diabetes | 131 (16.6%) | 148 (18.8%) | 0.26 | − 0.32 |
| Cancer | 69 (8.8%) | 80 (10.2%) | 0.34 | 1.66 |
| Chronic liver disease | 30 (3.8%) | 31 (3.9%) | 0.89 | − 1.24 |
| Non-renal SOFA score | 6 (4–9) | 6 (4–9) | 0.12 | 2.55 |
| Sepsis | 327 (41.5%) | 353 (44.8%) | 0.19 | 2.52 |
| Baseline creatinine (μmol/L) | 85 (66–98) | 83 (62–100) | 0.89 | 0.05 |
| Use of nephrotoxic drugs | 113 (14.7%) | 129 (16.4%) | 0.26 | − 1.68 |
| Mechanical ventilation | 541 (68.7%) | 544 (69.0%) | 0.87 | − 1.37 |
| Use of vasopressors | 260 (33.0%) | 291 (36.9%) | 0.10 | 1.03 |
Values are median (interquartile range) or n (%)
BMI body mass index, SOFA sequential organ failure assessment, COPD chronic obstructive pulmonary disease